van Houte Marthe, Harmsze Ankie M, Deneer Vera H M, Tupker Ron A
Department of Dermatology, St. Antonius Hospital, Nieuwegein, The Netherlands.
J Dermatolog Treat. 2008;19(2):101-4. doi: 10.1080/09546630701418754.
Oxybutynin has been proven to be effective in patients with generalized hyperhidrosis. Some dermatoses aggravate as a result of sweating. Therefore, oxybutynin might also be useful in such normohidrotic patients. The aim was to evaluate the efficacy and safety of different doses of oxybutynin on exercise-induced sweating in healthy individuals.
Two randomized, double-blind, placebo-controlled, cross-over studies were performed, in which two different dosages (2.5 and 5 mg) of oxybutynin were tested. The degree of sweating was determined by transepidermal water loss (TEWL) measurement on the forearm and the hand during exercise. Furthermore, the effectiveness was evaluated by means of the individual's global assessment score, and side effects were noted.
No significant differences between oxybutynin and placebo were found on the forearm and the hand at both dosages of oxybutynin with respect to TEWL values and the individual's global assessment score. Side effects consisted of diarrhoea, dizziness, dry mouth and dry eyes.
In this model, oxybutynin did not result in inhibition of exercise-induced sweating in healthy volunteers.
已证实奥昔布宁对全身性多汗症患者有效。一些皮肤病会因出汗而加重。因此，奥昔布宁对这类出汗正常的患者可能也有用。目的是评估不同剂量奥昔布宁对健康个体运动诱发出汗的疗效和安全性。
进行了两项随机、双盲、安慰剂对照、交叉研究，测试了两种不同剂量（2.5毫克和5毫克）的奥昔布宁。通过测量运动期间前臂和手部的经皮水分流失（TEWL）来确定出汗程度。此外，通过个体整体评估评分评估疗效，并记录副作用。
在奥昔布宁的两种剂量下，在前臂和手部，就TEWL值和个体整体评估评分而言，奥昔布宁与安慰剂之间未发现显著差异。副作用包括腹泻、头晕、口干和眼干。
在该模型中，奥昔布宁未对健康志愿者的运动诱发出汗产生抑制作用。
